Davis Gates

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 41 篇 · 总被引 822 次 · h-index 19

代表论文

• Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol (2016 · PLoS ONE · 被引 95)
• Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial (2025 · The Lancet · 被引 82)
• A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia (2019 · PLoS ONE · 被引 48)
• Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials (2025 · The Lancet · 被引 45)
• Intercycle variability of the ovarian response in patients undergoing repeated stimulation with corifollitropin alfa in a gonadotropin-releasing hormone antagonist protocol (2015 · Fertility and Sterility · 被引 40)
• Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis (2016 · Reproductive BioMedicine Online · 被引 36)